Effect of cinobufagin capsule on coagulation state, therapeutic effect and quality of life in patients with advanced lung cancer
10.3760/cma.j.issn.1008-6706.2019.14.004
- VernacularTitle: 华蟾素对晚期肺癌患者凝血状态、治疗效果和生活质量的影响
- Author:
Rurui GUO
1
;
Gensheng YANG
Author Information
1. Department of Respiratory Medicine, the Second People's Hospital of Jinzhong, Jinzhong, Shanxi 030800, China
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Huachansu Jiaonang;
Drug therapy, combination;
Blood coagulation factors;
Fibrinogen;
Blood platelets;
Quality of life;
Treatment outcome;
Controlled clinical trial
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(14):1679-1682
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effects of cinobufagin capsule on coagulation status, therapeutic effect and quality of life of patients with advanced lung cancer.
Methods:A total of 64 patients with advanced lung cancer admitted to the Second People's Hospital of Jinzhong from February 2017 to January 2018 were selected, and they were divided into control group and observation group by random number table method, with 32 cases in each group.The control group was treated with chemotherapy, and the observation group was treated with cinobufagin capsules combined with chemotherapy.Blood coagulation status, quality of life score, pain numerical rating scale (NRS) and functional status score(KPS) were observed before and after treatment in the two groups.The clinical efficacy was compared between the two groups.
Results:Before treatment, there were no statistically significant differences in plasma fibrinogen(FIB), platelet(PLT), D-dimer, quality of life score, NRS score and KPS score between the two groups(all P>0.05). After treatment, the FIB, PLI and D-dimers in the observation group were (3.6±0.9)g/L, (248.3±11.3)×109/L, (19.8±1.2)mg/L respectively, which were significantly lower than those in the control group [(4.5±0.6)g/L, (398.2±16.2)×109/L, (40.2±0.6)mg/L] (t=11.642, 21.045, 18.249, all P<0.05). The total effective rate of the observation group was 90.6%(29/32), which was significantly higher than 68.8%(22/32) of the control group(χ2=6.903, P<0.05). The quality of life scores of the two groups were improved, and the life scores of the observation group were significantly higher than those of the control group(t=11.642, 21.045, 18.249, 17.218, all P<0.05). The NRS score of the observation group (3.62±1.53)points was significantly lower than that of the control group[(5.01±2.34)points], and the KPS score of the observation group[(78.25±3.81)points] was significantly higher than that of the control group[(72.34±4.12)points], the differences were statistically significant (t=16.082, 15.082, all P<0.05).
Conclusion:Treatment of advanced lung cancer with cinobufagin capsule combined with chemotherapy can significantly improve the coagulation state, treatment effect and quality of life of patients.
